Agency for Science, Technology and Research

L'oreal

Simon McKenzie Cool

Victor Nurcombe

Christian Dombrowski

Raymond Alexander Alfred Smith

Sadasivam Murali

Lawrence W Stanton

Murali Sadasivam

Jonathan Lee

Ling Ling

Charbel Bouez

Padmapriya Sathiyanathan

Diah Saraswati Bramono

Rebekah M Samsonraj

Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.

Heparin and heparan sulphate oligosaccharides

A method for providing a sub-population of stem cell or plurality of stem cells by determining or modulating GSTT1 expression level or genotype is disclosed together with uses of the stem cells.

Stem cell subpopulations with differential GSTT1 expression or genotype

Affinity purification of platelet-derived growth factor-binding heparan sulphate from porcine mucosa (HS6) is disclosed. Also disclosed is the use of HS6 in repair and regeneration of the skin for treating wounds, burns, ulcers and other skin injuries.

PDGF-B /PDGF-BB binding variants of heparan sulfates

A heparan sulphate that binds TGP&#x3b2;1 is disclosed.

Heparan sulphates

Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is a process for the care of keratinous material(s), comprising the application or administration of HS8, or a composition comprising thereof, to keratinous material(s). The composition may be used to improve the condition of skin, such as smoothing the skin, restoring skin elasticity and firmness, or decreasing or preventing wrinkles, and may be formulated for topical or transdermal administration.

Cosmetic use of heparan sulphate

Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is the use of HS8 in repair and regeneration of the skin for treating wounds, burns, ulcers and other skin injuries.

Heparan sulphates for use in repair and/or regeneration of skin

A novel class of structurally and functionally related isolated Heparan sulphate is disclosed. The novel class of Heparan sulphates has been found to bind FGF2 and enhance the proliferation of stem cells while maintaining their pluripotency/multipotency.

Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and/or development and/or regeneration of tissue.

Glycosaminoglycans

Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue.

The invention relates to heparan sulphate GAGs obtained by affinity chromatography using the heparin-binding domain of BMP2. The GAGs were obtained from osteoblast extracellular matrix and from a commercially available heparan sulfate (Celsus HS).

Heparan sulphate which binds BMP2

Heparan sulphates isolated from male and female murine liver, their characterisation and use in pharmaceutical compositions, methods of treatment and in stem cell culture media suitable for conditions associated with bone repair.

Isolation and characterisation of heparan sulphates and their use in pharmaceutical compositions, methods of treatment and stem cell culture media suitable for conditions associated with bone repair

The use of an FGFR1 antibody in the treatment of cancer is disclosed, wherein the FGFR1 antibody binds FGFR1 at an epitope that is positioned in the FGFR1 primary amino acid sequence no more than 50 contiguous amino acids away from the C- or N-terminal of the FGFR1 heparin binding domain.

Growing community of inventors

Singapore, Singapore

Simon McKenzie Cool